|
Market Closed -
23:00:00 04/09/2026 +03
|
5-day change
|
1st Jan Change
|
|
2.670 USD
|
+1.91%
|
 |
+5.12%
|
+48.33%
|
|
08-12 |
Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026
| | |
08-12 |
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
|
CI
| |
08-12 |
Protalix: Q2 Earnings Snapshot
|
AQ
| |
08-12 |
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
|
PR
| |
08-12 |
Protalix BioTherapeutics, Inc. Reaffirms Earnings Guidance for the Year 2026
|
CI
| |
08-05 |
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
|
PR
| |
05-13 |
Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026
| | |
05-13 |
Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
|
CI
| |
05-13 |
Protalix BioTherapeutics : PLX Corporate Presentation (May 2026)
|
PU
| |
05-13 |
Protalix: Q1 Earnings Snapshot
|
AQ
| |
05-13 |
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
|
PR
| |
05-13 |
Protalix BioTherapeutics, Inc. Reaffirms Revenue Guidance for the Year 2026
|
CI
| |
05-06 |
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
|
PR
| |
03-19 |
Chiesi Global Rare Diseases and Protalix Biotherapeutics Announces European Commission Approval of an Add-On Every Four Weeks Dosing Regimen for Pegunigalsidase Alfa
|
CI
| |
03-18 |
Top Midday Decliners
|
MT
| |
03-18 |
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
|
CI
| |
03-18 |
Protalix BioTherapeutics, Inc., 2025 Earnings Call, Mar 18, 2026
| | |
03-18 |
Protalix BioTherapeutics, Inc. Provides Earnings Guidance for the Year 2026
|
CI
| |
03-18 |
Protalix Biotherapeutics reports fiscal year 2025 financial and business results
|
RE
| |
03-18 |
Protalix: Q4 Earnings Snapshot
|
AQ
| |
03-18 |
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
|
PR
| |
03-11 |
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
|
PR
| |
03-09 |
EU approves four-week dosing option for Chiesi and Protalix's Elfabrio
|
RE
| |
03-09 |
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
|
AQ
| |
03-09 |
Chiesi Global Rare Diseases and Protalix Biotherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio
|
CI
|
No results match your criteria Select your edition All financial news and data tailored to specific country editions | 
